Monimus Capital Management LP Purchases Shares of 7,296 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Monimus Capital Management LP purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 7,296 shares of the medical equipment provider’s stock, valued at approximately $653,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Aurora Investment Counsel boosted its position in shares of Lantheus by 0.8% in the fourth quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider’s stock worth $1,718,000 after buying an additional 146 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of Lantheus by 39.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 10,814 shares of the medical equipment provider’s stock worth $967,000 after buying an additional 3,045 shares during the period. Thompson Siegel & Walmsley LLC boosted its position in shares of Lantheus by 107.1% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 157,964 shares of the medical equipment provider’s stock worth $14,131,000 after buying an additional 81,680 shares during the period. Vestcor Inc boosted its position in shares of Lantheus by 9.7% in the fourth quarter. Vestcor Inc now owns 6,653 shares of the medical equipment provider’s stock worth $595,000 after buying an additional 591 shares during the period. Finally, Swiss National Bank boosted its position in shares of Lantheus by 1.0% in the fourth quarter. Swiss National Bank now owns 136,654 shares of the medical equipment provider’s stock worth $12,225,000 after buying an additional 1,300 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Finally, Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $132.86.

Lantheus Stock Up 1.8 %

LNTH opened at $101.10 on Friday. The firm has a market cap of $6.92 billion, a PE ratio of 16.82 and a beta of 0.38. The business has a fifty day simple moving average of $91.87 and a 200-day simple moving average of $96.90. Lantheus Holdings, Inc. has a fifty-two week low of $56.44 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.